Astrazeneca AB has patented new proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors reported to be useful for the treatment of cardiovascular disorders.
Astrazeneca AB has synthesized transient receptor potential cation channel subfamily V member 4 (TRPV4) antagonists reported to be useful for the treatment of inflammatory disorders, respiratory diseases, metabolic diseases, dermatological disorders, neuromuscular disorders, genetic disorders, cancer and pain, among others.
Astrazeneca AB has synthesized nicotinamide N-methyltransferase (NNMT) inhibitors reported to be useful for the treatment of chronic kidney disease, acute kidney injury and diabetic nephropathy.
Astrazeneca AB has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to an interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker acting as IRAK-4 degradation inducers reported to be useful for the treatment of cancer, inflammation, autoimmune diseases and respiratory disorders.
Astrazeneca AB has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a protein cereblon (CRBN) binding moiety covalently linked to an estrogen receptor α (ER-α)-targeting moiety through a linker reported to be useful for the treatment of breast cancer.
Astrazeneca AB has reported the identification of 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH; MASH), among others.
Astrazeneca AB has divulged 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of alcoholic liver disease, liver fibrosis, cirrhosis, hepatic steatosis, liver inflammation, hepatitis C virus (HCV) infection and liver cancer (hepatocellular carcinoma).
Astrazeneca AB has synthesized antibody-drug conjugates comprising an antibody or antigen-binding fragment covalently linked to cytotoxic moieties through enzymatically cleavable linkers reported to be useful for the treatment of cancer.
Astrazeneca has identified anthracycline compounds and antibody-drug conjugates consisting of an antibody covalently bound to anthracycline derivatives reported to be useful for the treatment of cancer.
Astrazeneca AB patents describe new proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)-targeting moiety reported to be useful for the treatment of cancer.
